Please Wait
Applying Filters...
menu
    • menu
    Farmak works in the development, production and marketing of APIs, Intermediates & Specialties// FDA inspected.

    Virtual Booth

    Contact Supplier

    Minakem delivers API, HPAPI, steroids & CDMO services for generics with FDA/GMP certification, regulatory know-how & proven success.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-01-12

    Virtual Booth

    An Enquiry

    IKF/Pharmasynthese have been with fine chemicals market and APIs performance for more than 40 years.

    Virtual Booth

    Contact Supplier

    Cosma S.p.A., part of CFM Group with AMSA & Clarochem, provides global pharma & veterinary health with 300+ tons of FDA-approved APIs.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    An Enquiry

    Menu

    Sodium Thiosulfate

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 0Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Fennec Pharma Announces Trial for Metastatic TGCT at City of Hope
    Fennec Pharma Announces Trial for Metastatic TGCT at City of Hope

    09 Dec 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/12/09/3202214/0/en/Fennec-Pharmaceuticals-Announces-Investigator-Sponsored-Trial-to-Be-Conducted-by-City-of-Hope-in-Metastatic-Testicular-Germ-Cell-Tumors.html

    GLOBENEWSWIRE
    09 Dec 2025
    Share Share
    Fennec Pharma Reports PEDMARK Study Success In Japan
    Fennec Pharma Reports PEDMARK Study Success In Japan

    02 Dec 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/12/02/3197763/0/en/Fennec-Pharmaceuticals-Announces-Positive-Topline-Results-From-Investigator-Initiated-Clinical-Study-of-PEDMARK-in-Japan-to-Reduce-Cisplatin-Induced-Hearing-Loss.html

    GLOBENEWSWIRE
    02 Dec 2025
    Share Share
    NICE makes first-of-a-kind recommendation for hearing loss drug
    NICE makes first-of-a-kind recommendation for hearing loss drug

    06 Jan 2025

    // PHARMAREVIEW

    https://www.europeanpharmaceuticalreview.com/news/240759/nice-makes-first-of-a-kind-recommendation-for-hearing-loss-drug/

    PHARMAREVIEW
    06 Jan 2025
    Share Share
    Cipla`s Generics Sodium Thiosulfate Receives Tentative Approval in US
    Cipla`s Generics Sodium Thiosulfate Receives Tentative Approval in US

    01 Nov 2024

    // FDA

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=218028

    FDA
    01 Nov 2024
    Share Share
    Fennec Pharmaceuticals and Norgine Enter into Exclusive Licensing Agreement
    Fennec Pharmaceuticals and Norgine Enter into Exclusive Licensing Agreement

    18 Mar 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/fennec-pharmaceuticals-and-norgine-enter-into-exclusive-licensing-agreement-to-commercialize-pedmarqsi-in-europe-australia-and-new-zealand-302090953.html

    PR NEWSWIRE
    18 Mar 2024
    Share Share
    FDA Issues Reminder of Non-Substitution of PEDMARK for Pediatric Patients
    FDA Issues Reminder of Non-Substitution of PEDMARK for Pediatric Patients

    01 Feb 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com//news-release/2024/02/01/2821780/0/en/FDA-Issues-Reminder-of-Non-Substitution-of-PEDMARK-sodium-thiosulfate-injection-for-Pediatric-Patients-Receiving-Cisplatin.html

    GLOBENEWSWIRE
    01 Feb 2024
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.